JFJose Carlos Ferreira

Jose Carlos Ferreira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jose Carlos Ferreira has a total of 319 co-authors. Here are the top co-authors by number of shared publications:

  • Sanaa Choufani

    Genetics and Genome Biology Program, Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada

    10 shared publications
  • Rosanna Weksberg

    Genetics and Genome Biology Program, Research Institute, the Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; Division of Clinical and Metabolic Genetics, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada

    7 shared publications
  • Federico Maggi

    Unit of Research and Development, Cytogenetics and Medical Genetics TOMA, Advanced Biomedical Assays, Impact Lab Group, Busto Arsizio, Varese, Italy

    6 shared publications
  • Giuseppe Simoni

    Unit of Research and Development, Cytogenetics and Medical Genetics TOMA, Advanced Biomedical Assays, Impact Lab Group, Busto Arsizio, Varese, Italy

    6 shared publications
  • Darci T. Butcher

    Genetics and Genome Biology Program, Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada

    5 shared publications
  • Daria Grafodatskaya

    Genetics and Genome Biology Program, Hospital for Sick Children Research Institute, Toronto, ON M5G 1X8, Canada

    5 shared publications

Latest Publications

  • Open Access

    The minimum requirements for prenatal “confirmatory” diagnosis of fetal aneuploidy

    by Jose Carlos Ferreira, Brynn Levy, Peter Benn

  • Termination of pregnancy for fetal malformations and severe genetic disorders: what are the laws in Europe?

    by Silvia Kalantari, Raquel Gouveia Silva, Mridul Johari, José Carlos Ferreira, Mirella Parachini


  • Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA

    by Francesca Romana Grati, Jose Ferreira, Peter Benn, Claudia Izzi, Federica Verdi, Elena Vercellotti, Cristina Dalpiaz, Patrizia D’aJello, Elisa Filippi, Nicola Volpe, et al.


  • Response to Toutain et al.

    by Peter Benn, Jose Ferreira, Francesca Romana Grati


  • Open Access

    Anthropometric features as predictors of atherogenic dyslipidemia and cardiovascular risk in a large population of school-aged children

    by José M Furtado, Sílvia M Almeida, Paulo Mascarenhas, Maria E Ferraz, José C Ferreira, Manuel Vilanova, Mariana P Monteiro, Fernando P Ferraz

    Autopsy studies reveal that atherosclerosis lesions can be found as early as two years of age. To slow the development of this early pathology, obesity and dyslipidemia prevention should start from childhood making it urgent to explore new ways to evaluate dyslipidemia risk in children that can be applied widely, such as the non-invasive anthropometric evaluation. Assess the metabolic profile of a pediatric population at a specific age to describe the association between anthropometric and biochemical cardiovascular disease risk factors; and evaluate selected anthropometric variables as potential predictors for dyslipidemic cardiovascular risk. Anthropometric features, bioimpedance parameters and fasting clinical profile were assessed in Lisbon and the Tagus Valley region pre-pubertal nine-year-old children (n = 1.496) from 2009–2013 in a descriptive, cross-sectional study. Anthropometric variables predictive power was evaluated through regression analysis. At least one abnormal lipid parameter was found in 65% of “normal weight”, 73% of “overweight” and 81% of “obese” children according to the International Obesity Task Force (IOTF) standards. Dyslipidemia was present in 67.8% of children. Waist-hip ratio (WHR) explained 0.4% of total cholesterol (TC) variance. Waist circumference (WC) explained 2.8% of apolipoprotein (APO) A1 variance. Waist-circumference-to-height-ratio (WHtR) explained 2.7%, 2.8% and 1.9% of low-density lipoprotein cholesterol (LDL-c), APO B, and N_HDL-c variance, respectively. Children with abnormally high WHR levels had an increase in risk of 4.49, 3.40 and 5.30 times, respectively, for developing cardiovascular disease risk factors measured as high-risk levels of TC, LDL-c and non-HDL-c (N_HDL-c) (p<0.05). Only 29.9% of “normal weight” children had no anthropometric, bioimpedance or biochemical parameters associated with CV risk. A large proportion of school age children have at least one lipid profile abnormality. BMI, zBMI, calf circumference (CC), hip circumference (HC), WC, and WHR are directly associated with dyslipidemia, whereas HC and calf circumference (CC) adjusted to WC, and mid-upper arm circumference (MUAC), are all inversely associated with dyslipidemia. Selected anthropometric variables are likely to help predict increased odds of having CV risk factors.


  • Open Access

    Association between LEPR, FTO, MC4R, and PPARG-2 polymorphisms with obesity traits and metabolic phenotypes in school-aged children

    by Sílvia M. Almeida, José M. Furtado, Paulo Mascarenhas, Maria E. Ferraz, José C. Ferreira, Mariana P. Monteiro, Manuel Vilanova, Fernando P. Ferraz

    Evaluate the relationship of leptin receptor (LEPR) rs1137101, fat mass obesity-associated (FTO) receptors 9939609, melanocortin-4 receptors (MC4R) rs2229616 and rs17782313, and proliferator-activated receptor-gamma (PPARG) rs1801282 with clinical and metabolic phenotypes in prepubertal children.


  • Implications of fetoplacental mosaicism on cell‐free DNA testing for sex chromosome aneuploidies

    by Francesca Romana Grati, Komal Bajaj, Valentina Zanatta, Francesca Malvestiti, Barbara Malvestiti, Livia Marcato, Beatrice Grimi, Federico Maggi, Giuseppe Simoni, Susan J. Gross, et al.

    Objective: The unique biological behavior of sex chromosomes has implications for cell‐free DNA (cfDNA) testing. Our purpose is to predict the (1) false positive/negative rates of cfDNA testing consequent to fetoplacental mosaicism for any sex chromosome aneuploidies (SCA) and (2) positive predictive value (PPV) and negative predictive values of a high‐risk and low‐risk cfDNA result for any SCA.Method: This is a retrospective analysis of 67 030 chorionic villus sampling karyotypes, including fetoplacental mosaicism cases.Results: Non‐mosaic 45, X is associated with cystic hygroma/increased nuchal translucency and fetal anomalies. The false positive rate consequent to confined placental mosaicism is predicted to be 0.05%. The estimated false negative rate is in the range of 0% to 5.7% for all non‐mosaic SCAs; it is 70% for mosaic 45, X with normal ultrasound. The predicted PPV on amniocytes is very high for most SCAs (94.4–99.4%). However, the stratified analysis shows that the PPV is much lower for 45, X without ultrasound anomalies compared with 45, X with abnormal scan (51% or 71%, vs 99%, respectively).Conclusion: Mosaicism is a major issue for SCA cfDNA testing, and prenatal confirmation, preferentially with amniocentesis if there are no ultrasound anomalies, remains important in counseling. As PPV varies on the basis of the presence of an ultrasound anomaly, skilled evaluation is critical. © 2017 John Wiley & Sons, Ltd.


  • Frequency of fetal karyotype abnormalities in women undergoing invasive testing in the absence of ultrasound and other high-risk indications

    by Jose Carlos P. Ferreira, Francesca R. Grati, Komal Bajaj, Francesca Malvestiti, Maria Beatrice Grimi, Anna Trotta, Rosaria Liuti, Silvia Milani, Lara Branca, Jacob Hartman, et al.

    No previous studies have reported the frequencies of individual chromosomal anomalies in normal-appearing fetuses stratified by maternal age (MA) and gestational age (GA). We therefore sought to (1) characterize the frequency of all fetal karyotype anomalies in sonographically normal appearing fetuses without pretest risk factors, and (2) assess MA and GA impact on the proportion of anomalies targeted by screening and consequent impact on residual risk following a negative result. Fetal karyotypes from samples without prior risk assessment or ultrasound anomalies were analyzed. We calculated, per single-year MA and in two GA intervals, the predicted frequency of each cytogenetic defect. A total of 129 263 karyotypes were analyzed. The risk for significant, cytogenetically visible chromosomal anomalies, at 15 to 20 weeks GA, varies between 1/301 at MA of 18 years, and 1/9 at MA of 48 years. The proportion of clinically significant anomalies not addressed by current screening methods is 47% at MA of 18 years and 5% at MA of 48 years. By determining frequencies for individual karyotype anomalies stratified by MA and GA, in the setting of normal-appearing fetuses, a more personalized risk assessment, including the residual risk after a normal fetal aneuploidy screening result, can be provided. © 2016 John Wiley & Sons, Ltd.


  • Open Access

    Anthropometric predictors of body fat in a large population of 9‐year‐old school‐aged children

    by Sílvia M Almeida, José M Furtado, Paulo Mascarenhas, Maria E Ferraz, Luís R Silva, José C Ferreira, Mariana Monteiro, Manuel Vilanova, Fernando P Ferraz

    Summary: Objective: To develop and cross‐validate predictive models for percentage body fat (%BF) from anthropometric measurements [including BMI z‐score (zBMI) and calf circumference (CC)] excluding skinfold thickness.Methods: A descriptive study was carried out in 3,084 pre‐pubertal children. Regression models and neural network were developed with %BF measured by Bioelectrical Impedance Analysis (BIA) as the dependent variables and age, sex and anthropometric measurements as independent predictors.Results: All %BF grade predictive models presented a good global accuracy (≥91.3%) for obesity discrimination. Both overfat/obese and obese prediction models presented respectively good sensitivity (78.6% and 71.0%), specificity (98.0% and 99.2%) and reliability for positive or negative test results (≥82% and ≥96%). For boys, the order of parameters, by relative weight in the predictive model, was zBMI, height, waist‐circumference‐to‐height‐ratio (WHtR) squared variable (_Q), age, weight, CC_Q and hip circumference (HC)_Q (adjusted r2 = 0.847 and RMSE = 2.852); for girls it was zBMI, WHtR_Q, height, age, HC_Q and CC_Q (adjusted r2 = 0.872 and RMSE = 2.171).Conclusion: %BF can be graded and predicted with relative accuracy from anthropometric measurements excluding skinfold thickness. Fitness and cross‐validation results showed that our multivariable regression model performed better in this population than did some previously published models.


  • The type of feto‐placental aneuploidy detected by cfDNA testing may influence the choice of confirmatory diagnostic procedure

    by Francesca Romana Grati, Komal Bajaj, Francesca Malvestiti, Cristina Agrati, Beatrice Grimi, Barbara Malvestiti, Eva Pompilii, Federico Maggi, Susan Gross, Giuseppe Simoni, et al.

    Objectives: Cell‐free DNA (cfDNA) screening can provide false positive/negative results because the fetal fraction originates primarily from trophoblast. Consequently, invasive diagnostic testing is recommended to confirm a high‐risk result. Currently, there is debate about the most appropriate invasive method. We sought to estimate the frequency in which a chorionic villus sampling (CVS) performed after a high‐risk cfDNA result would require a follow‐up amniocentesis due to placental mosaicism.Methods: Analyses of the frequencies of the different types of mosaicism involving cytotrophoblasts, for trisomies 21 (T21), 18 (T18), 13 (T13) and monosomy X (MX) among 52 673 CVS karyotypes obtained from cytotrophoblast, mesenchyme and confirmatory amniocentesis.Results: After a high‐risk cfDNA result for T21, 18, 13 and MX, the likelihood of finding CVS mosaicism and need for amniocentesis is, respectively, 2%, 4%, 22% and 59%. When mosaicism is detected by CVS, the likelihood of fetal confirmation by amniocentesis is, respectively, 44%, 14%, 4% and 26%.Conclusions: In cases of high‐risk cfDNA results for T21/T18, CVS (combining cytotrophoblast and mesenchyme analysis) can be considered, but with the caveat of 2–4% risk of an inconclusive result requiring further testing. In high‐risk results for MX/T13, amniocentesis would appear to be the most appropriate follow‐up diagnostic test, especially in the absence of sonographic findings. © 2015 John Wiley & Sons, Ltd.